Article Text

PDF

Letter
Isolated limb dystonia as presenting feature of Parkin disease
  1. Antonio E Elia1,
  2. Francesca Del Sorbo1,
  3. Luigi M Romito1,
  4. Chiara Barzaghi1,2,
  5. Barbara Garavaglia2,
  6. Alberto Albanese1,3
  1. 1 Neurologia I, Istituto Neurologico Carlo Besta, Milano, Italy
  2. 2 Neurogenetica Molecolare, Istituto Neurologico Carlo Besta, Milano, Italy
  3. 3 Istituto di Neurologia, Università Cattolica del Sacro Cuore, Milano, Italy
  1. Correspondence to Professor Alberto Albanese, Fondazione Istituto Neurologico Carlo Besta, Via G. Celoria 11, Milano 20133, Italy; alberto.albanese{at}unicatt.it

Statistics from Altmetric.com

Parkin related disease (OMIM 602544) is a common cause of autosomal recessive young-onset Parkinson's disease (PD). The motor phenotype encompasses parkinsonian features, dystonia, sustained response to levodopa and slow progression. It has been occasionally reported that patients may present with dystonia at onset.1 Isolated lower limb dystonia is a typical presentation of early-onset generalised dystonia, often indicating a DYT1 carrier status. DYT1 and non-DYT1 cases have also been described with onset in adulthood. It is presently unknown in how many such cases dystonia may be the presenting feature of Parkin disease.

We observed a series of Parkin gene mutation carriers who had isolated limb dystonia as the presenting feature of their disorder that lasted for several years before parkinsonian features developed. We report the clinical description of eight such cases; four patients are illustrated in the online supplementary video. Parkin gene mutations were detected according to standard procedures.2 Eight had isolated dystonia at onset. These subjects had full neurological evaluation and videotape documentation. These patients had regular follow-up twice a year, including a complete neurological and motor examination. The levodopa equivalent dose (LED, measured in milligrams)3 was calculated at each visit. Non-motor features were assessed using the Non-Motor Symptom Assessment Scale for PD.

Out of a total of 44 Parkin mutation carriers, 36 (81.8%) had parkinsonian features at onset, either with or without dystonia. Eight patients (18.2%) had isolated dystonia for an average of 5.0±6.4 years (range 1–16) before parkinsonian features became apparent (table 1). In all these cases, lower limb task-specific dystonia activated by walking was the presenting feature. Three patients had also lower limb pain unrelated to dystonic spasms. Their mean age at onset was 28.9±14.2 years. Onset was unilateral in six patients, bilateral in the remaining two. In all patients, 123I-FP-CIT SPECT imaging showed a bilateral reduction of striatal tracer uptake.

Table 1

Demographic and clinical features of Parkin disease patients

The mean follow-up was 11.5±5.9 years. In two patients, dystonia progressed and lost task specificity to occur also at rest. No patient developed cranial or cervical dystonia; the upper limbs became involved by dystonia later in the disease in three patients (patients 5, 6 and 8), on average 3.3±2.1 years after onset, and distal tremor developed in two of them (patients 5 and 6).

We observed improvement of lower limbs dystonia after dopaminergic treatment in six patients (patients 3, 4, 5, 6, 7 and 8) and mild effect in two (patients 1 and 2). The mean LED was 157.5±67.8. In patient 8, complete benefit was observed in legs but no improvement was observed in writer's cramp.

Onset of dystonia in these patients resembled the presentation of DYT1 phenomenology, with limb onset and activation by walking. Three of these patients were initially thought to have DYT1 dystonia and one was misdiagnosed as having dopa-responsive dystonia (DRD). Progression was not typical for DYT1 because generalisation, which is a common feature of DYT1 dystonia, did not occur. Normal genetic testing allowed ruling out mutations in the DYT1, DYT6 and DRD genes and 123I-FP-CIT SPECT imaging allowed identifying dopaminergic denervation in the striatum.

Dystonia at disease onset has been estimated to affect 14%–57% of young-onset PD patients with dystonic onset being particularly common in patients under age 48.4 Genetic forms with dystonia at onset include many possible alternatives, such as DRD, Wilson's disease, X-linked dystonia–parkinsonism/Lubag, rapid-onset dystonia–parkinsonism and syndromes of neurodegeneration with brain iron accumulation. Recently, a patient carrying a THAP1 gene mutation was also reported to be affected by lower limb dystonia.5

In Parkin disease, particularly, dystonia at onset may occur in >40% of cases.6 We observe here that isolated dystonia can last up to 16 years before parkinsonian symptoms develop in Parkin gene mutation carriers and that dystonic onset can also occur in patients aged >40. In these patients, dystonia at onset and the associated pain responded well to dopaminergic treatment, similar to what is observed in DRD. A positive DAT SPECT scan can lead the differential diagnosis in the right direction. Remarkably, in previous studies of patients with adult-onset lower limb dystonia, no patient was investigated for Parkin gene mutations.7 ,8 We suggest that Parkin related disease be considered in patients with lower limb dystonia, regardless of age at onset.

References

View Abstract

Review history and Supplementary material

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Footnotes

  • Contributors AEE, AA, FDS, LMR, BG and CB: conception and design, analysis and interpretation of data. AA, AEE, FDS and LMR: performed clinical assessment of patients and acquisition of data. AEE and FDS performed literature review and drafted the paper. BG and CB carried on the genetic studies. AEE, AA, FDS, LMR, BG and CB critically revised the paper for intellectual content and final approved the version to be submitted for publication.

  • Funding Supported by Ministry of Health grant GR-2009-1607326 to AEE and by COST Action BM1101 to AA.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.